aXichem AB (publ) ("aXichem" or the "Company") announces that the Company has received guarantee commitments free of charge (so-called "top-down guarantees") in the ongoing exercise of warrants series TO1A where the exercise period ends on October 21, 2024 (“TO1A”). The guarantee commitments comprise a total of SEK 2.0 million, corresponding to approximately 11 percent of the issue proceeds the Company can receive through the exercise of TO1A.
In connection with the ongoing exercise of warrants series TO1A, aXichem has received guarantee commitments free of charge from a number of qualified investors. The guarantee commitments comprise a total of SEK 2.0 million, corresponding to approximately 11 percent of the issue proceeds the Company can receive through the exercise of TO1A. The guarantee commitments are so-called "top-down guarantees", which means that the guaranteed amount of SEK 2 million is added to the current subscription level for TO1A. The guarantee commitments will therefore not be utilized in the event that TO1A is fully exercised by existing holders of the warrants. The guarantee commitments are not secured by bank guarantee, restricted funds, pledged assets or similar arrangements.
In the event that the guarantee commitments are utilized, subscription of shares will take place through a directed share issue which will be carried out after the exercise period for TO1A has ended. The right to subscribe in the directed share issue shall only fall upon the investors that have provided guarantee commitments, and subscription must take place at the determined subscription price for TO1A and only to the extent that warrants series TO1A has not been exercised by existing holders within the size of the guarantee commitments (equivalent to a maximum of 2,105,263 shares of class A in the Company).
More information about warrants series TO1A, as well as complete terms and instructions, is available on the Company's website www.axichem.com.
Certified adviser for aXichem is Västra Hamnen Corporate Finance AB.
The information was submitted, through the agency of the above contact person, for publication on October 16, 2024, at 23:00 CEST.
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey, as an ingredient in food supplements for gut health, weight control and sports and exercise, and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com
